Herbas VPB

Print
EN | LT
LT - Vėžio gydymas naudojant anti-CD19 chimerinį antigeno receptorių
EN - TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR

Legal status

Patent in force

Bibliographic data
Indications of the International Patent Classification (IPC)
(51) INT.CL. C12N 5/0783 (2010.01)
A61K 35/17 (2015.01)
A61K 31/00 (2006.01)
A61P 35/02 (2006.01)
European patent
(11) Number of the document 3129470
(13) Kind of document T
(96) European patent application number 15719043.0
Date of filing the European patent application 2015-04-07
(97) Date of publication of the European application 2017-02-15
(45) Date of publication and mention of the grant of the patent 2021-04-07
(46) Date of publication of the claims translation 2021-07-12
PCT application
(86) Number PCT/US2015/024671
Date 2015-04-07
PCT application publication
(87) Number WO 2015/157252
Date 2015-10-15
Priority applications
(30) Number Date Country code
201461976396 P 2014-04-07 US
201462007309 P 2014-06-03 US
201462036493 P 2014-08-12 US
201462076238 P 2014-11-06 US
201462087888 P 2014-12-05 US
201462097278 P 2014-12-29 US
Inventors
(72)
BYRD, John, US
DUBOVSKY, Jason, US
FRAIETTA, Joseph, US
GILL, Saar, US
GLASS, David, US
JOHNSON, Amy, US
JUNE, Carl, H., US
KENDERIAN, Saad, US
MANNICK, Joan, US
MAUS, Marcela, US
MURPHY, Leon, US
MUTHUSAMY, Natarajan, US
PORTER, David, L., US
RUELLA, Marco, US
SELLERS, William, Raj, US
WASIK, Mariusz, US
BROGDON, Jennifer, US
Grantee
(73) NOVARTIS AG, Lichtstrasse 35, 4056 Basel, CH
The Trustees of The University of Pennsylvania, 3160 Chestnut Street Suite 200, Philadelphia, PA 19104, US
Attorney or representative
(74) Vitalija BANAITIENĖ, UAB TARPINĖ, A.P.Kavoliuko g. 24-152, LT-04328 Vilnius, LT
Title
(54) Vėžio gydymas naudojant anti-CD19 chimerinį antigeno receptorių
  TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
Last renewal fee
Payment date Validity (years) Amount
2026-03-18 12 289.00 EUR
Next renewal fee
2027-04-07